Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...

Vector Laboratories, a manufacturing partner of reagents and critical components for the development and production of life sciences tools, diagnostics, and clinical-stage biotherapeutics, today ...

OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Researchers have identified a gene therapy that could prevent life-threatening arrhythmias by restoring the heart’s ...

Mechelen, Belgium Monday, February 17, 2025, 16:00 Hrs [IST] ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.

The proof-of-concept study is one of the first to combine B and T cell analysis and potentially paves the way for tests that ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

Vector-borne zoonotic diseases, transmitted by pathogens via arthropods like mosquitoes, ticks, and fleas, comprise 17% of the global infectious disease ...